Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Cancer Metastatic × Tamoxifen × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 53 Carcinoma, Intraductal, Noninfiltrating 7 Breast Carcinoma In Situ 5 Neoplasms 3 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Breast Neoplasms, Male 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Precancerous Conditions 1 Multiple Endocrine Neoplasia Type 1 1 Inflammatory Breast Neoplasms 1 Infertility 1 Hyperglycemia 1 Glioblastoma 1 Endometrial Neoplasms 1 Endometrial Hyperplasia 1 ERα+ Breast Cancer 1 Carcinoma, Lobular 1 Breast Cancer Subjects 1 Breast Cancer Metastatic 1 Breast Cancer Female 1 Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Fulvestrant 3 Letrozole 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 ribociclib 1 irinotecan sucrosofate 1 exemestane 1 abemaciclib 1 Zoledronic Acid 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Gemcitabine 1 Anastrozole 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡